The Filing Desk

Stoke Therapeutics

STOK · Nasdaq · Health Care · Financials, fiscal 2018 to 2025

STOK · Last close · November 13, 2026
$26.68
Value Stoke Therapeutics yourself

Stoke Therapeutics' revenue rose 404.5% to $184 million in fiscal 2025. Its operating margin was −11.2%, up from −277.3% a year earlier. Free cash flow was $45 million. The diluted share count rose 9.7%.

Stoke Therapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 16, 2026 · 0001193125-26-108362 Updated
Revenue
$184M
404.5%
Operating margin
−11.2%
266.1 pts
Net income
−$7M
 
Free cash flow
$45M
 
Return on equity
−2.4%
43.4 pts
Market cap
$1.8B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Stoke Therapeutics does

Stoke Therapeutics is a late-stage clinical company that develops medicines for severe genetic diseases. It has no approved product. Its approach, which it calls TANGO, uses antisense oligonucleotides (short pieces of genetic material) to raise the amount of a protein the body makes too little of. This targets diseases caused by having only about half the normal protein level, starting with diseases of the brain and the eye.

Its lead candidate, zorevunersen, is being tested for Dravet syndrome, a severe genetic epilepsy that starts in the first year of life and causes frequent seizures and developmental delays. The company says no approved medicine treats the underlying causes of Dravet. A global Phase 3 trial began in 2025, following earlier studies in the United States and the United Kingdom. A second candidate targets a genetic eye disease called autosomal dominant optic atrophy.

Stoke has no product revenue. It works with Biogen, which has rights to the Dravet candidate outside the United States, Canada and Mexico, and may receive milestone and royalty payments from it.

Its biggest risks, as it describes them

  • Its business depends on zorevunersen and its other candidates succeeding in trials and winning approval.
  • Early results may not hold up in later trials, and regulators may not approve its medicines.
  • Diseases that few people have are hard to enroll in trials, which can cause delays.
  • It relies on Biogen and on outside firms for trials, supply and parts of its work.
  • It has a history of losses and may need to raise more money.
From Stoke Therapeutics's annual report on Form 10-K, filed March 16, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Stoke Therapeutics lost money in fiscal 2025: a net loss of $7 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments220230201217285
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage——−2,342.3x−3,898.9x−2,287.8x
Current ratio13.4x7.8x7.0x5.8x5.3x
Quick ratio13.4x7.8x7.0x5.8x5.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Stoke Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Stoke Therapeutics shares on the open market, and 8 insiders sold $8.7 million, $7.2 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 1, 2026Barry TichoChief Medical OfficerSold plan5,545$30.67$170,058Form 4
Aug 18, 2026Edward M. MD KayeDirectorSold12,567$32.03$402,563Form 4
Aug 18, 2026Barry TichoChief Medical OfficerSold4,767$32.03$152,703Form 4
Aug 18, 2026Jonathan AllanGeneral Counsel & Corp SecSold2,861$32.03$91,647Form 4
Aug 3, 2026Barry TichoChief Medical OfficerSold plan7,176$29.04$208,380Form 4
Jul 1, 2026Barry TichoChief Medical OfficerSold plan7,228$32.66$236,102Form 4
Jun 16, 2026Jonathan AllanGeneral Counsel & Corp SecSold plan1,457$29.95$43,637Form 4
Jun 1, 2026Barry TichoChief Medical OfficerSold plan1,795$30.58$54,891Form 4
May 1, 2026Barry TichoChief Medical OfficerSold plan2,243$32.79$73,548Form 4
Apr 1, 2026Barry TichoChief Medical OfficerSold plan1,838$32.66$60,029Form 4
Mar 20, 2026Jonathan AllanGeneral Counsel & Corp SecSold plan9,293$33.69$313,079Form 4
Mar 19, 2026Barry TichoChief Medical OfficerSold plan1,461$29.99$43,815Form 4
The latest 12 of 40 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−970.9%78.2%428.9%
Altman Z''−1.381.915.29
Accruals ratio−9.8%−0.8%−15.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Stoke Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Stoke TherapeuticsFY25404.5%−11.2%24.4%———
Rhythm PharmaceuticalsFY2545.8%−101.2%−61.5%——6Compare
Syndax PharmaceuticalsFY25627.8%−158.4%−187.5%———Compare
LiquidiaFY251,031.2%−32.5%−25.3%———Compare
IDEAYA BiosciencesFY253,024.4%−72.8%−33.6%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue————12937184
Revenue growth—————−29.2%316.3%404.5%
Gross profit————————
Research and development8243254788289138
Operating income−13−36−53−86−104−115−101−21
Net income−12−32−52−86−101−105−89−7
Diluted EPS (US$)−17.65−1.80−1.56−2.34−2.60−2.38−1.65−0.12
Diluted shares (millions)118343739445459
Cash flow
Cash from operations−11−31−42−67−32−81−8746
Capital expenditure12114201
Free cash flow−12−33−43−68−36−83−8745
Dividends paid00000000
Share buybacks00000000
Acquisitions00000000
Stock-based compensation0261623252832
Balance sheet at fiscal year end
Cash and short-term investments105222287220230201217285
Debt incl. finance leases————————
Total assets108229298239256228272418
Total liabilities24122171694266
Shareholders' equity105224286218185160229352
Margins and ratios
Gross margin————————
Operating margin————−841.2%−1,307.2%−277.3%−11.2%
Net margin————−814.7%−1,192.5%−243.4%−3.7%
Free cash flow margin————−288.8%−941.7%−238.2%24.4%
Rule of 40 (growth + FCF margin)—————−970.9%78.2%428.9%
Return on capital————————
Return on equity—−19.6%−20.5%−34.1%−50.2%−60.8%−45.8%−2.4%
Return on assets—−19.2%−19.8%−32.0%−40.8%−43.2%−35.6%−2.0%
Net debt to EBITDA————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Stoke Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Stoke Therapeutics.